Romidepsin
HDAC inhibitor / A potent and selective inhibitor of class I histone deacetylases (HDACs), IC50 = 36, 47, 510 and 14,000 nM for HDAC1, 2, 4 and HDAC6, respectively1. Induces apoptosis in a variety of cell lines2 and displays antitumor activity in mouse models3. Recently approved for clinical use in T-cell lymphoma4.
Biochemicals & reagents
128517-07-7
FK-228; FR901228; Depsipeptide
1) Furumai et al. (2002), FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases; Cancer Res.., 62 4916 2) Panicker et al. (2010), Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells; Cell Cycle, 9 1830 3) Ueda et al. (1994), FR901228, a novel anti-tumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice; J. Antibiot. (Tokyo), 47 315 4) VanderMolin et al. (2011), Romodepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma; J. Antibiotic. (Tokyo), 64 525
-20°C
TARGET: Protein deacetylase -- PATHWAY: Chromatin; Apoptosis inducer; Posttranslational modification -- RESEARCH AREA: Epigenetics; Cell death -- DISEASE AREA: Cancer